Eledon Pharmaceuticals (NASDAQ:ELDN) Stock Rating Raised to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Eledon Pharmaceuticals (NASDAQ:ELDN – Free Report) from a strong sell rating to a sell rating in a report published on Saturday,Wall Street Zen reports.

Several other equities analysts have also recently issued reports on the company. Weiss Ratings upgraded Eledon Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, November 9th. Rodman & Renshaw started coverage on Eledon Pharmaceuticals in a report on Tuesday, July 21st. They issued a “buy” rating and a $12.00 price objective for the company. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

Read Our Latest Report on Eledon Pharmaceuticals

Eledon Pharmaceuticals Price Performance

Shares of Eledon Pharmaceuticals stock traded down $0.25 on Friday, hitting $2.12. The company had a trading volume of 1,510,708 shares, compared to its average volume of 908,634. The business has a 50-day simple moving average of $2.56 and a 200-day simple moving average of $3.11. The company has a market cap of $172.27 million, a PE ratio of -2.90 and a beta of 0.95. Eledon Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $4.49.

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. On average, equities research analysts predict that Eledon Pharmaceuticals will post -0.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ELDN. Legal & General Group Plc bought a new stake in shares of Eledon Pharmaceuticals during the 2nd quarter worth $28,000. StoneX Group Inc. acquired a new position in shares of Eledon Pharmaceuticals in the 3rd quarter worth $29,000. Waverly Advisors LLC acquired a new stake in shares of Eledon Pharmaceuticals during the first quarter worth $39,000. Grandfield & Dodd LLC acquired a new stake in shares of Eledon Pharmaceuticals during the second quarter worth $39,000. Finally, Claro Advisors Inc. acquired a new stake in shares of Eledon Pharmaceuticals during the third quarter worth $40,000. Institutional investors own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

(Get Free Report)

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious diseases involving the immune system. The company’s research focuses on modulating immune responses to help address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS). Its lead investigational product, tegoprubart, is an antibody that targets CD40 ligand, a protein involved in immune-system activation. Eledon is studying tegoprubart as a potential treatment to reduce rejection following organ transplantation and in research involving ALS.

Recommended Stories

Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.